The global health organization Coalition for Epidemic Preparedness Innovations (CEPI) announced Monday that it will "urgently accelerate development" of three vaccine candidates against Bundibugyo ebolavirus (BDBV), pledging a little over $60 million in the effort to extinguish an outbreak currently raging out of control in the Democratic Republic of the Congo.
Under the plans, CEPI has committed up to $50 million to US-based Moderna for preclinical development and Phase 1 clinical testing of its mRNA-based BDBV vaccine candidate. The funding will simultaneously allow the company to ramp up manufacturing capabilities and ready large-scale Phase 2/3 trials in the event the vaccine makes it through early testing. The vaccine will use Moderna's mRNA vaccine platform that allowed for rapid development of a COVID-19 vaccine during the pandemic.
"[W]e believe our mRNA platform can play an important role in responding rapidly to emerging infectious disease threats," Moderna CEO Stéphane Bancel said in a statement Monday. " We will move with urgency and scientific rigor to support the response and help bring a potential vaccine closer to the communities that need it most."
DW News 
